Detail akcie BIOMED-LUBLIN online

Business Summary: Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Synthaverse SA revenues increased 1% to PLN13.6M. Net loss increased from PLN538K to PLN3.6M. Revenues reflect Sales of Services - Net increase of 16% to PLN107K. Higher net loss reflects Interest Expense increase from PLN758K to PLN2.4M (expense), General Expenses increase of 19% to PLN8.7M (expense), Total Financial Expense - Balancing v increase from PLN156K to PLN975K (expense).